Ulises Martinez Ortega | Medicinal Chemistry | Young Scientist Award

Published on by Global Academic Awards

Dr. Ulises Martinez Ortega | Medicinal Chemistry | Young Scientist Award

Professor | National Autonomous University of Mexico | Mexico

Dr. Ulises Martinez-Ortega’s research focuses on computational chemistry, molecular modeling, and drug design, particularly targeting cancer-related pathways such as EGFR inhibition. With 3 publications, 11 citations across 11 documents, and an h-index of 2, his work contributes to the development of quinazoline-based compounds with therapeutic potential. He applies advanced computational techniques, including free energy calculations, to optimize molecular interactions. His research supports the discovery of efficient, targeted treatments and advances understanding in medicinal chemistry and pharmaceutical development.

Citation Metrics (Scopus)

12

10

8

6

4

2

0

Citations
11

Documents
3

h-index
2

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Profile
 View ORCID Profile
 View Google Scholar Profile

Featured Publications

Alchemical Free Energy-Based Optimization of Quinazoline Derivatives as Potent EGFR Inhibitors with Cytotoxic Activity
– Bioorganic and Medicinal Chemistry, 2025

Computational Design and Evaluation of Quinazoline-Based Compounds for Targeted Cancer Therapy
– Medicinal Chemistry Research

Molecular Modeling and Drug Design Approaches for EGFR Inhibitors in Cancer Treatment
– Journal of Molecular Modeling

Jing Nie | Medicinal Chemistry | Best Researcher Award

Published on by Global Academic Awards

Ms. Jing Nie | Medicinal Chemistry | Best Researcher Award

Ms. Jing Nie | Shandong Second Provincial General Hospital | China

Ms. Jing Nie serves as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital and holds the position of Associate Chief Pharmacist. She actively contributes to the advancement of pharmaceutical sciences through her leadership roles in various professional committees, including the Shandong Provincial Hospital Association’s Digital and Intelligent Pharmacy Committee, the Pediatric Rational Drug Use Committee of the Shandong Pharmacists Association, and the Otolaryngology Pharmacy Committee of the Shandong Pharmaceutical Society. She is also a core member of the Rheumatology Committee of the Jinan Association of Integrated Traditional Chinese and Western Medicine, the Antitumor Drug Committee of the Shandong Pharmaceutical Society, the Tumor Pharmacy Branch of the Shandong Anti-Cancer Association, and the Internet Plus Pharmacy Services Committee. Her research focuses on hospital pharmacy, artificial intelligence, pharmacoeconomics, and antitumor drug development. She has published extensively, secured patents, developed software, and led multiple provincial and collaborative projects while contributing to numerous national-level studies.

Publication Profile

Scopus

Education

Ms. Jing Nie earned her doctoral degree in pharmacy, equipping her with a strong academic foundation to contribute to both scientific research and clinical pharmacy practice. Her education combined rigorous theoretical learning with extensive research experience, allowing her to specialize in the integration of hospital pharmacy with advanced technologies such as artificial intelligence and pharmacoeconomics. During her doctoral training, she focused on evidence-based approaches to optimize drug therapy and explored the mechanisms and applications of antitumor drugs. Her academic journey not only strengthened her technical expertise but also instilled in her a deep commitment to innovation, patient safety, and rational drug use. She has built upon her formal education through continuous professional development, actively engaging with academic societies, conferences, and specialized committees that broaden her knowledge and keep her at the forefront of evolving pharmaceutical sciences. Her educational background remains the cornerstone of her contributions to research and practice.

Experience

Ms. Jing Nie has extensive professional experience as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital, where she also serves as Associate Chief Pharmacist. Her experience includes leadership and active participation in multiple prestigious committees, such as those dedicated to digital pharmacy, rational pediatric drug use, otolaryngology pharmacy, rheumatology, and oncology. She has played a key role in advancing pharmaceutical sciences by bridging hospital pharmacy with innovative fields like artificial intelligence and pharmacoeconomics. Her experience is further reflected in her strong publication record, where she has authored and co-authored more than twenty scientific papers, many in high-impact journals. She has successfully applied her expertise to provincial-level projects, cross-disciplinary collaborations, and has contributed significantly to national-level studies. In addition, her practical work includes obtaining multiple patents and software copyrights, reinforcing her ability to translate scientific innovation into practical applications that benefit patients and the healthcare system.

Research Focus

Ms. Jing Nie’s research focus lies at the intersection of pharmaceutical sciences, oncology, and innovative therapeutic strategies. Her work on the advances of HDAC dual inhibitors in breast cancer treatment highlights her commitment to exploring novel drug mechanisms and targeted therapies in oncology. By investigating epigenetic regulation through HDAC inhibition, she contributes to the development of more effective treatments for breast cancer patients, bridging basic research with clinical applications. Beyond oncology, her broader focus includes hospital pharmacy, pharmacoeconomics, artificial intelligence in drug management, and rational drug use. This multidisciplinary approach allows her to integrate clinical practice with cutting-edge research, addressing both the economic and therapeutic aspects of patient care. Her emphasis on anti-tumor drug development, combined with her role in scientific committees and leadership positions, reflects a holistic vision of improving healthcare outcomes through innovation, collaboration, and translational research. Ms. Nie’s focus is well aligned with advancing precision medicine and modern pharmacy.

Publication Top Notes

Advances of HDAC dual inhibitors in breast cancer treatment

Conclusion

Ms. Jing Nie is highly suitable for the Research for Best Researcher Award, given her impactful contributions to pharmaceutical sciences, leadership roles, and innovation in anti-tumor drug research and artificial intelligence. With strategic international engagement and clinical translation of her work, she has the potential to become a globally recognized leader in hospital pharmacy research.

Baijayantimala Swain | Pharmaceutical Medicinal Chemistry Award | Best Researcher Award

Published on by Global Academic Awards

Dr. Baijayantimala Swain | Pharmaceutical Medicinal Chemistry Award | Best Researcher Award

Dr. Baijayantimala Swain, bharat institute of technology- pharmacy, India

Dr. Baijayantimala Swain is an accomplished medicinal chemist with expertise in drug design and discovery, specializing in carbonic anhydrase inhibitors. With a Ph.D. from NIPER Hyderabad, she has synthesized novel compounds targeting various isoforms of carbonic anhydrase, crucial in diseases like cancer and glaucoma. 🧪 Her research has led to the development of potent molecules with therapeutic potential. Dr. Swain’s multidisciplinary skills encompass organic synthesis, analytical techniques, and computational chemistry. She is recognized for her contributions to scientific literature and holds a strong academic background, fostering collaborative research in pharmaceutical sciences. 🎓

 

Publication Profile

Scopus

Academic Qualification 

Dr. Baijayantimala Swain forged her path in pharmaceutical sciences. From her Bachelor’s in Pharmaceutical Sciences at Sri Jaydev College in Odisha, India 🎓, she ventured into deeper realms with a Master’s in Medicinal Chemistry at NIPER, Hyderabad, delving into the intricacies of peptide synthesis for anticancer endeavors. Driven by an insatiable thirst for knowledge, she pursued a Ph.D. in Medicinal Chemistry at the same institute, where she honed her skills in designing novel inhibitors for carbonic anhydrases, under the guidance of esteemed mentors. Each milestone illuminated her academic odyssey, shaping her into a versatile researcher.

 

Research Focus 🧪

Dr. Baijayantimala Swain’s research primarily revolves around the design and synthesis of novel compounds targeting carbonic anhydrases, key enzymes involved in various physiological processes. Her work spans the development of diverse chemical entities, including sulfonamide and non-sulfonamide derivatives, ureidosulfocoumarin derivatives, and indole-based hybrids. These compounds hold promise as potential inhibitors of specific isoforms of carbonic anhydrases, with implications for therapeutic intervention in conditions such as cancer and other diseases. Through innovative approaches and meticulous experimentation, Dr. Swain contributes to the advancement of medicinal chemistry, striving to unlock new avenues for drug discovery and development.

 

Publication Top Notes 
  1. “Design, synthesis, and biological evaluation of 3-benzenesulfonamide-linked 3-hydrazinoisatin derivatives as carbonic anhydrase inhibitors” (2024)
  2. “Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors” (2022) – cited by 1
  3. “Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors” (2022) – cited by 7
  4. “Efficient One-pot Synthesis of 3,3-di(indolyl)indolin-2-ones from Isatin and Indole Catalyzed by VOSO4 as Non-Sulfonamide Carbonic Anhydrase Inhibitors” (2022) – cited by 1
  5. “Exploration of 2-phenylquinoline-4-carboxamide linked benzene sulfonamide derivatives as isoform selective inhibitors of transmembrane human carbonic anhydrases” (2022) – cited by 6
  6. “Design and development of novel series of indole-3-sulfonamide ureido derivatives as selective carbonic anhydrase II inhibitors” (2022) – cited by 5
  7. “Design and synthesis of benzenesulfonamide-linked imidazo[2,1-b][1,3,4]thiadiazole derivatives as carbonic anhydrase I and II inhibitors” (2021) – cited by 6